Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pediatric dalteparin study for venous thromboembolism
NL-OMON46293Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of dalteparin in venous thromboembolism (VTE), sponsored by Pfizer. Primary endpoints: Median dose required to achieve therapeutic anti-Xa and Anti-Xa activity population pharmacodynamic profile. Planned start Mar 2017; status: withdrawn.
02
Drugs
dalteparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON46293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46293.